Drugs with this side effect as MedDRA Preferred Term
- 2-hydroxysuccinaldehyde
- 5-FU
- 5-aza-2'-deoxycytidine
- A77 1726
- BPTI
- Bivalirudin
- Myocardial infarction: postmarketing
- CAS 76095-16-4
- Myocardial infarction: 1.2%
- CAS 76420-72-9
- Myocardial infarction: postmarketing
- Cancidas
- Eptifibatide
- Myocardial infarction: 0.0962%
- Estrofem
- FAMP
- FK463
- Fe(III
- Gd-DTPA
- Ge-132
- Glat copolymer
- Myocardial infarction: postmarketing
- Goserelin
- Myocardial infarction: postmarketing
- Insulin
- K779
- L-Dmp
- Myocardial infarction: rare
- LMWH
- Lantus
- Leuprorelin
- Myocardial infarction: postmarketing
- Lisinopril
- Myocardial infarction: postmarketing, uncommon
- Lovaza
- Meropenem anhydrous
- Nafarelin
- Myocardial infarction: postmarketing
- Oestrogen
- Myocardial infarction: rare
- PGE1
- PGE2
- Photofrin
- SU5416
- SonoVue
- Stalevo 50
- Terlipressin
- Myocardial infarction: postmarketing
- Triptorelin
- Myocardial infarction: postmarketing
- Trisequens
- UDCA
- abacavir
- Myocardial infarction: postmarketing
- abiraterone
- acamprosate
- Myocardial infarction: infrequent
- adenosine
- Myocardial infarction: postmarketing
- almotriptan
- amifostine
- amitriptyline
- amlodipine besylate
- amoxapine
- Myocardial infarction: postmarketing
- amphetamine
- amphotericin B
- amprenavir
- Myocardial infarction: postmarketing
- anagrelide
- anastrozole
- Myocardial infarction: 1.29% - 1.36%
- anthracycline
- aprepitant
- argatroban
- Myocardial infarction: 3.57% - 3.6%
- aripiprazole
- atenolol
- Myocardial reinfarction: 0% - 6%
- atropine
- axitinib
- Myocardial infarction: 1.4%
- benazepril
- betaxolol
- bezafibrate
- bicalutamide
- bisoprolol
- bleomycin hydrochloride
- bortezomib
- bosentan
- bromocriptine
- Myocardial infarction: postmarketing
- bupropion
- Myocardial infarction: postmarketing, rare
- buspirone
- Myocardial infarction: rare
- candesartan
- candesartan cilexetil
- capecitabine
- carbidopa
- carboplatin
- carvedilol
- Myocardial infarction: 0.9% - 2.2%
- cefdinir
- Myocardial infarction: postmarketing
- celecoxib
- cevimeline
- cilazapril
- Myocardial infarction: postmarketing, 0.1% - 0.3%
- cilostazol
- ciprofloxacin
- Myocardial infarction: postmarketing
- cisplatin
- citalopram
- Myocardial infarction: postmarketing, infrequent, uncommon
- clevidipine
- clomipramine
- Myocardial infarction: rare
- clozapine
- Myocardial infarction: postmarketing
- colesevelam
- colestyramine
- conjugated estrogens
- Myocardial infarction: postmarketing
- copolymer 1
- Myocardial infarction: postmarketing
- cortisol
- cortisone
- cyclobenzaprine
- Myocardial infarction: postmarketing
- cyclophosphamide
- Myocardial infarction: postmarketing
- Myocardial necrosis
- cyproterone
- Myocardial infarction: 4%
- cyproterone acetate
- dabigatran
- dabigatran etexilate
- dalteparin
- danazol
- dapagliflozin
- darunavir
- Myocardial infarction: uncommon, 0.2%
- dasatinib
- degarelix
- deprenyl
- Myocardial infarction: rare
- desflurane
- Myocardial infarction: postmarketing
- desipramine
- desvenlafaxine
- dexamethasone
- dexamethasone sodium phosphate
- dexmedetomidine
- Myocardial infarction: postmarketing
- diatrizoate
- diazepam
- diclofenac
- Myocardial infarction: very rare
- dihydroergotamine
- Myocardial infarction: postmarketing
- diltiazem
- Myocardial infarction: postmarketing
- dipyridamole
- docetaxel
- Myocardial infarction: very rare, postmarketing
- dofetilide
- dolasetron
- Myocardial infarction: postmarketing
- donepezil
- Myocardial infarction: infrequent
- dorzolamide
- dothiepin
- doxazosin
- Myocardial infarction: postmarketing, 1% - 1.3%
- drospirenone (DRSP
- duloxetine
- Myocardial infarction: postmarketing, infrequent
- eletriptan
- entacapone
- Myocardial infarction: uncommon, common
- epinephrine
- eplerenone
- Myocardial infarction: common
- ergonovine
- erlotinib
- esmolol
- Myocardial infarction
- Inferior myocardial infarction
- estradiol
- Myocardial infarction: postmarketing
- estradiol cypionate
- estradiol valerate
- estramustine
- Myocardial infarction: 1% - 3%
- estramustine phosphate
- estriol
- estrone
- etodolac
- Myocardial infarction: postmarketing
- etoposide
- etoricoxib
- etravirine
- everolimus
- exemestane
- febuxostat
- fenofibrate
- fenoldopam
- ferumoxytol
- Myocardial infarction: postmarketing
- fludarabine
- Myocardial infarction: 0% - 3%
- fluoxetine
- Myocardial infarction: infrequent
- flurbiprofen
- fluvoxamine
- Myocardial infarction: rare, infrequent
- formoterol
- fosamprenavir
- Myocardial infarction: uncommon
- fosinopril
- fosinoprilat
- frovatriptan
- gabapentin
- Myocardial infarction: rare, infrequent
- gadodiamide
- gemcitabine
- Myocardial infarction: postmarketing, rare
- gemeprost
- gliclazide
- guanfacine
- Myocardial infarction: postmarketing
- heparin
- hydrochlorothiazide
- ibuprofen
- idarubicin
- ifosfamide
- Myocardial infarction: postmarketing
- imatinib
- Myocardial infarction: rare
- imipramine
- imiquimod
- Myocardial infarction: postmarketing
- indinavir
- Myocardial infarction: postmarketing
- insulin detemir
- iodixanol
- iopamidol
- iopromide
- Myocardial infarction: postmarketing
- ioversol
- ioxaglate
- irbesartan
- Myocardial infarction: rare
- irbesartan-hydrochlorothiazide
- irinotecan
- iron sucrose
- isomannide
- isosorbide-5-mononitrate
- isradipine
- ixabepilone
- ketoprofen
- Myocardial infarction: postmarketing
- ketorolac
- Myocardial infarction: postmarketing
- ketorolac tromethamine
- lamotrigine
- Myocardial infarction: rare
- lanreotide
- lansoprazole
- lenalidomide
- Myocardial infarction: postmarketing
- lercanidipine
- letrozole
- Myocardial infarction: 0.276% - 15%
- leuprorelin acetate
- levodopa/carbidopa
- lisdexamfetamine dimesylate
- Myocardial infarction: postmarketing
- lomefloxacin
- maprotiline
- maraviroc
- medroxyprogesterone
- medroxyprogesterone acetate
- mefenamic acid
- meloxicam
- Myocardial infarction: postmarketing
- memantine
- Myocardial infarction: infrequent
- meropenem
- methylphenidate
- methylprednisolone
- methylprednisolone sodium succinate
- metipranolol
- mirtazapine
- Myocardial infarction: postmarketing, infrequent
- misoprostol
- Myocardial infarction: postmarketing
- mitoxantrone
- moexiprilat
- moxifloxacin
- mycophenolate mofetil
- nabumetone
- Myocardial infarction: postmarketing, 0.1%
- naltrexone
- naproxen
- naratriptan
- Myocardial infarction: very rare
- nebivolol
- Myocardial infarction: postmarketing
- nicardipine
- Myocardial infarction: 0.6%
- nicorandil
- Myocardial infarction: uncommon
- nilotinib
- Myocardial infarction: uncommon
- nisoldipine
- norethisterone
- norfloxacin
- nortriptyline
- ofloxacin
- ogen
- ondansetron
- Myocardial infarction: postmarketing
- oxaprozin
- paclitaxel
- Myocardial infarction: rare, common
- pantoprazole
- parecoxib
- paroxetine
- Myocardial infarction: rare
- pazopanib
- pemetrexed
- pergolide
- Myocardial infarction: infrequent, 1.1%
- perindopril
- Myocardial infarction: very rare
- phentermine
- phentolamine
- Myocardial infarction: common
- phenylephrine
- pilocarpine
- pioglitazone
- piroxicam
- ponatinib
- Myocardial infarction: 2.9%
- posaconazole
- potassium phosphate
- Myocardial infarction: rare
- pramipexole
- pravastatin
- Myocardial infarction: 0.5%
- prednisolone
- prednisolone acetate
- prednisone
- pregabalin
- Myocardial infarction: infrequent
- propofol
- propoxyphene
- prostacyclin
- protriptyline
- quinapril
- rabeprazole
- raltegravir
- ramipril
- Myocardial infarction: 0.3% - 1.7%
- rasagiline
- Myocardial infarction: infrequent, uncommon
- regadenoson
- Myocardial infarction: postmarketing, uncommon
- regorafenib
- repaglinide
- rescinnamine
- Myocardial infarction: 1.4%
- retinoic acid
- ribavirin
- Myocardial infarction: uncommon
- riluzole
- Myocardial infarction: infrequent
- risperidone
- Myocardial infarction: infrequent
- ritonavir
- Myocardial infarction: postmarketing
- rivastigmine
- Myocardial infarction: frequent
- rizatriptan
- Myocardial infarction: postmarketing
- rofecoxib
- ropinirole
- Myocardial infarction: infrequent
- ropivacaine
- rosiglitazone
- salmon calcitonin acetate
- sertraline
- Myocardial infarction: postmarketing, rare
- sibutramine
- sildenafil
- Myocardial infarction: postmarketing, rare
- sitaxsentan
- sodium
- sodium ferric gluconate
- sorafenib
- sotalol
- strontium ranelate
- sumatriptan
- Myocardial infarction: very rare
- tacrolimus
- Myocardial infarction: postmarketing
- tadalafil
- Myocardial infarction: postmarketing
- tamoxifen
- telmisartan
- Myocardial infarction: postmarketing
- tenoxicam
- testosterone
- Myocardial infarction: postmarketing
- tetrahydrobiopterin
- thalidomide
- Myocardial infarction: postmarketing
- thyroxine
- tiagabine
- Myocardial infarction: infrequent
- tibolone
- tirofiban
- tizanidine
- Myocardial infarction: rare
- tolcapone
- Myocardial infarction: infrequent
- toremifene
- Myocardial infarction: 0.498% - 1.4%
- tramadol
- trandolapril
- Myocardial infarction: postmarketing
- trandolaprilat
- Myocardial infarction: postmarketing
- tranexamic acid
- trazodone
- Myocardial infarction: postmarketing
- triamcinolone
- triamcinolone acetonide
- triiodothyronine
- trimipramine
- ustekinumab
- v 1784
- Myocardial infarction: postmarketing
- valdecoxib
- vardenafil
- varenicline
- Myocardial infarction: postmarketing, infrequent
- venlafaxine
- Myocardial infarction: rare
- verapamil
- Myocardial infarction: postmarketing
- verteporfin
- vinblastine
- vincristine
- vinflunine
- vinorelbine
- voriconazole
- vorinostat
- zolmitriptan
- Myocardial infarction: postmarketing, rare
- zolpidem
- Myocardial infarction: rare
|
Drugs with this indication
|